Randomized, observer-blind, placebo-controlled study to assess the immunogenicity and safety of two adjuvant formulations of an egg-derived pandemic surface antigen influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Trial Profile

Randomized, observer-blind, placebo-controlled study to assess the immunogenicity and safety of two adjuvant formulations of an egg-derived pandemic surface antigen influenza vaccine in healthy adults aged greater than or equal to 18 years and less than or equal to 49 years.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs Aluminium hydroxide; Influenza A virus vaccine-H5N1
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Oct 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Aug 2008 Planned end date changed from 1 Aug 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
    • 04 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top